Pharmaceuticals - Global Group of Eight (G8) Industry Guide

Pharmaceuticals - Global Group of Eight (G8) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the G8 (United States, Canada, Germany, France, United Kingdom, Italy, Russia and Japan) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

• Contains an executive summary and data on value, volume and segmentation
• Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies
• Incorporates in-depth five forces competitive environment analysis and scorecards
• Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country. .
• Includes a five-year forecast of the industry

Highlights

The G8 countries contributed $510,182.1 million in 2010 to the global pharmaceuticals industry, with a compound annual growth rate (CAGR) of 3.9% between 2006 and 2010.

The G8 countries are expected to reach a value of $629,493.5 million in 2015, with a CAGR of 4.3% over the 2010–15 period.

Among the G8 countries, the US holds the major share of the pharmaceuticals industry. It accounted for a share of 52.1% in 2010.

Among the G8 nations, the US is the leading country in the pharmaceuticals industry, with market revenues of $265,735.9 million in 2010.

The US is expected to lead the Pharmaceuticals industry in the G8 nations with a value of $346,744.2 million in 2015.
Why you should buy this report

• Spot future trends and developments
• Inform your business decisions
• Add weight to presentations and marketing materials
• Save time carrying out entry-level research

Market Definition

The pharmaceuticals market consists of ethical drugs for in-patient and out-patient usage, valued at ex-manufacturer prices.
Any currency conversions used within this report have been calculated using 2010 constant exchange rates.

Contents

INTRODUCTION

What is this report about?
Who is the target reader?
Market definition

GROUP OF EIGHT (G8) PHARMACEUTICALS INDUSTRY OUTLOOK

PHARMACEUTICALS IN CANADA

Market overview
Market value
Market segmentation
Market share
Five forces analysis
Leading companies
Market forecasts
Macroeconomic indicators

PHARMACEUTICALS IN FRANCE

Market overview
Market value
Market segmentation
Market share
Five forces analysis
Leading companies
Market forecasts
Macroeconomic indicators

PHARMACEUTICALS IN GERMANY

Market overview
Market value
Market segmentation
Market share
Five forces analysis
Leading companies
Market forecasts
Macroeconomic indicators

PHARMACEUTICALS IN ITALY

Market overview
Market value
Market segmentation
Market share
Five forces analysis
Leading companies
Market forecasts
Macroeconomic indicators

PHARMACEUTICALS IN JAPAN

Market overview
Market value
Market segmentation
Market share
Five forces analysis
Leading companies
Market forecasts
Macroeconomic indicators

PHARMACEUTICALS IN RUSSIA

Market overview
Market value
Market segmentation
Market share
Five forces analysis
Leading companies
Market forecasts
Macroeconomic indicators

PHARMACEUTICALS IN THE UNITED KINGDOM

Market overview
Market value
Market segmentation
Market share
Five forces analysis
Leading companies
Market forecasts
Macroeconomic indicators

PHARMACEUTICALS IN THE UNITED STATES

Market overview
Market value
Market segmentation
Market share
Five forces analysis
Leading companies
Market forecasts
Macroeconomic indicators

APPENDIX

Data Research Methodology
About Datamonitor
Disclaimer

LIST OF TABLES

Table 1: G8 pharmaceuticals industry, revenue($m), 2006–15
Table 2: G8 pharmaceuticals industry, revenue by country ($m), 2006–10
Table 3: G8 pharmaceuticals industry forecast, revenue by country ($m), 2010–15
Table 4: Canada pharmaceuticals market value: $ million, 2006–10
Table 5: Canada pharmaceuticals market segmentation: % share, by value, 2010
Table 6: Canada pharmaceuticals market share: % share, by value, 2010
Table 7: AstraZeneca PLC: key facts
Table 8: AstraZeneca PLC: key financials ($)
Table 9: AstraZeneca PLC: key financial ratios
Table 10: Johnson & Johnson: key facts
Table 11: Johnson & Johnson: key financials ($)
Table 12: Johnson & Johnson: key financial ratios
Table 13: Pfizer Inc.: key facts
Table 14: Pfizer Inc.: key financials ($)
Table 15: Pfizer Inc.: key financial ratios
Table 16: Canada pharmaceuticals market value forecast: $ million, 2010–15
Table 17: Canada size of population (million), 2006–10
Table 18: Canada gdp (constant 2000 prices, $ billion), 2006–10
Table 19: Canada gdp (current prices, $ billion), 2006–10
Table 20: Canada inflation, 2006–10
Table 21: Canada consumer price index (absolute), 2006–10
Table 22: Canada exchange rate, 2006–10
Table 23: France pharmaceuticals market value: $ million, 2006–10
Table 24: France pharmaceuticals market segmentation: % share, by value, 2010
Table 25: France pharmaceuticals market share: % share, by value, 2010
Table 26: AstraZeneca PLC: key facts
Table 27: AstraZeneca PLC: key financials ($)
Table 28: AstraZeneca PLC: key financial ratios
Table 29: GlaxoSmithKline Plc: key facts
Table 30: GlaxoSmithKline Plc: key financials ($)
Table 31: GlaxoSmithKline Plc: key financials (£)
Table 32: GlaxoSmithKline Plc: key financial ratios
Table 33: Pfizer Inc.: key facts
Table 34: Pfizer Inc.: key financials ($)
Table 35: Pfizer Inc.: key financial ratios
Table 36: France pharmaceuticals market value forecast: $ million, 2010–15
Table 37: France size of population (million), 2006–10
Table 38: France gdp (constant 2000 prices, $ billion), 2006–10
Table 39: France gdp (current prices, $ billion), 2006–10
Table 40: France inflation, 2006–10
Table 41: France consumer price index (absolute), 2006–10
Table 42: France exchange rate, 2006–10
Table 43: Germany pharmaceuticals market value: $ million, 2006–10
Table 44: Germany pharmaceuticals market segmentation: % share, by value, 2010
Table 45: Germany pharmaceuticals market share: % share, by value, 2010
Table 46: GlaxoSmithKline Plc: key facts
Table 47: GlaxoSmithKline Plc: key financials ($)
Table 48: GlaxoSmithKline Plc: key financials (£)
Table 49: GlaxoSmithKline Plc: key financial ratios
Table 50: Novartis AG: key facts
Table 51: Novartis AG: key financials ($)
Table 52: Novartis AG: key financial ratios
Table 53: Pfizer Inc.: key facts
Table 54: Pfizer Inc.: key financials ($)
Table 55: Pfizer Inc.: key financial ratios
Table 56: Germany pharmaceuticals market value forecast: $ million, 2010–15
Table 57: Germany size of population (million), 2006–10
Table 58: Germany gdp (constant 2000 prices, $ billion), 2006–10
Table 59: Germany gdp (current prices, $ billion), 2006–10
Table 60: Germany inflation, 2006–10
Table 61: Germany consumer price index (absolute), 2006–10
Table 62: Germany exchange rate, 2006–10
Table 63: Italy pharmaceuticals market value: $ million, 2006–10
Table 64: Italy pharmaceuticals market segmentation: % share, by value, 2010
Table 65: Italy pharmaceuticals market share: % share, by value, 2010
Table 66: Chiesi Farmaceutici SpA: key facts
Table 67: GlaxoSmithKline Plc: key facts
Table 68: GlaxoSmithKline Plc: key financials ($)
Table 69: GlaxoSmithKline Plc: key financials (£)
Table 70: GlaxoSmithKline Plc: key financial ratios
Table 71: Menarini Group, The: key facts
Table 72: Pfizer Inc.: key facts
Table 73: Pfizer Inc.: key financials ($)
Table 74: Pfizer Inc.: key financial ratios
Table 75: Italy pharmaceuticals market value forecast: $ million, 2010–15
Table 76: Italy size of population (million), 2006–10
Table 77: Italy gdp (constant 2000 prices, $ billion), 2006–10
Table 78: Italy gdp (current prices, $ billion), 2006–10
Table 79: Italy inflation, 2006–10
Table 80: Italy consumer price index (absolute), 2006–10
Table 81: Italy exchange rate, 2006–10
Table 82: Japan pharmaceuticals market value: $ million, 2006–10
Table 83: Japan pharmaceuticals market segmentation: % share, by value, 2010
Table 84: Japan pharmaceuticals market share: % share, by value, 2010
Table 85: Astellas: key facts
Table 86: Astellas: key financials ($)
Table 87: Astellas: key financials (¥)
Table 88: Astellas: key financial ratios
Table 89: Daiichi Sankyo Co., Ltd.: key facts
Table 90: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 91: Daiichi Sankyo Co., Ltd.: key financials (¥)
Table 92: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 93: Pfizer Inc.: key facts
Table 94: Pfizer Inc.: key financials ($)
Table 95: Pfizer Inc.: key financial ratios
Table 96: Japan pharmaceuticals market value forecast: $ million, 2010–15
Table 97: Japan size of population (million), 2006–10
Table 98: Japan gdp (constant 2000 prices, $ billion), 2006–10
Table 99: Japan gdp (current prices, $ billion), 2006–10
Table 100: Japan inflation, 2006–10
Table 101: Japan consumer price index (absolute), 2006–10
Table 102: Japan exchange rate, 2006–10
Table 103: Russia pharmaceuticals market value: $ million, 2006–10
Table 104: Russia pharmaceuticals market segmentation: % share, by value, 2010
Table 105: Russia pharmaceuticals market share: % share, by value, 2010
Table 106: Novartis AG: key facts
Table 107: Novartis AG: key financials ($)
Table 108: Novartis AG: key financial ratios
Table 109: Pharmstandard OJSC: key facts
Table 110: Pharmstandard OJSC: key financials ($)
Table 111: Pharmstandard OJSC: key financials (RUB)
Table 112: Pharmstandard OJSC: key financial ratios
Table 113: Sanofi-Aventis SA: key facts
Table 114: Sanofi-Aventis SA: key financials ($)
Table 115: Sanofi-Aventis SA: key financials (€)
Table 116: Sanofi-Aventis SA: key financial ratios
Table 117: Russia pharmaceuticals market value forecast: $ million, 2010–15
Table 118: Russia size of population (million), 2006–10
Table 119: Russia gdp (constant 2000 prices, $ billion), 2006–10
Table 120: Russia gdp (current prices, $ billion), 2006–10
Table 121: Russia inflation, 2006–10
Table 122: Russia consumer price index (absolute), 2006–10
Table 123: Russia exchange rate, 2006–10
Table 124: United Kingdom pharmaceuticals market value: $ million, 2006–10
Table 125: United Kingdom pharmaceuticals market segmentation: % share, by value, 2010
Table 126: United Kingdom pharmaceuticals market share: % share, by value, 2010
Table 127: AstraZeneca PLC: key facts
Table 128: AstraZeneca PLC: key financials ($)
Table 129: AstraZeneca PLC: key financial ratios
Table 130: GlaxoSmithKline Plc: key facts
Table 131: GlaxoSmithKline Plc: key financials ($)
Table 132: GlaxoSmithKline Plc: key financials (£)
Table 133: GlaxoSmithKline Plc: key financial ratios
Table 134: Pfizer Inc.: key facts
Table 135: Pfizer Inc.: key financials ($)
Table 136: Pfizer Inc.: key financial ratios
Table 137: United Kingdom pharmaceuticals market value forecast: $ million, 2010–15
Table 138: United Kingdom size of population (million), 2006–10
Table 139: United Kingdom gdp (constant 2000 prices, $ billion), 2006–10
Table 140: United Kingdom gdp (current prices, $ billion), 2006–10
Table 141: United Kingdom inflation, 2006–10
Table 142: United Kingdom consumer price index (absolute), 2006–10
Table 143: United Kingdom exchange rate, 2006–10
Table 144: United States pharmaceuticals market value: $ million, 2006–10
Table 145: United States pharmaceuticals market segmentation: % share, by value, 2010
Table 146: United States pharmaceuticals market share: % share, by value, 2010
Table 147: GlaxoSmithKline Plc: key facts
Table 148: GlaxoSmithKline Plc: key financials ($)
Table 149: GlaxoSmithKline Plc: key financials (£)
Table 150: GlaxoSmithKline Plc: key financial ratios
Table 151: Johnson & Johnson: key facts
Table 152: Johnson & Johnson: key financials ($)
Table 153: Johnson & Johnson: key financial ratios
Table 154: Merck & Co., Inc.: key facts
Table 155: Merck & Co., Inc.: key financials ($)
Table 156: Merck & Co., Inc.: key financial ratios
Table 157: Pfizer Inc.: key facts
Table 158: Pfizer Inc.: key financials ($)
Table 159: Pfizer Inc.: key financial ratios
Table 160: United States pharmaceuticals market value forecast: $ million, 2010–15
Table 161: United States size of population (million), 2006–10
Table 162: United States gdp (constant 2000 prices, $ billion), 2006–10
Table 163: United States gdp (current prices, $ billion), 2006–10
Table 164: United States inflation, 2006–10
Table 165: United States consumer price index (absolute), 2006–10
Table 166: United States exchange rate, 2006–10

LIST OF FIGURES

Figure 1: G8 pharmaceuticals industry, revenue($m), 2006–15
Figure 2: G8 Pharmaceuticals industry, revenue by country (%), 2010
Figure 3: G8 pharmaceuticals industry, revenue by country ($m), 2006–10
Figure 4: G8 pharmaceuticals industry forecast, revenue by country ($m), 2010–15
Figure 5: Canada pharmaceuticals market value: $ million, 2006–10
Figure 6: Canada pharmaceuticals market segmentation: % share, by value, 2010
Figure 7: Canada pharmaceuticals market share: % share, by value, 2010
Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2010
Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2010
Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2010
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2010
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2010
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2010
Figure 14: AstraZeneca PLC: revenues & profitability
Figure 15: AstraZeneca PLC: assets & liabilities
Figure 16: Johnson & Johnson: revenues & profitability
Figure 17: Johnson & Johnson: assets & liabilities
Figure 18: Pfizer Inc.: revenues & profitability
Figure 19: Pfizer Inc.: assets & liabilities
Figure 20: Canada pharmaceuticals market value forecast: $ million, 2010–15
Figure 21: France pharmaceuticals market value: $ million, 2006–10
Figure 22: France pharmaceuticals market segmentation: % share, by value, 2010
Figure 23: France pharmaceuticals market share: % share, by value, 2010
Figure 24: Forces driving competition in the pharmaceuticals market in France, 2010
Figure 25: Drivers of buyer power in the pharmaceuticals market in France, 2010
Figure 26: Drivers of supplier power in the pharmaceuticals market in France, 2010
Figure 27: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2010
Figure 28: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2010
Figure 29: Drivers of degree of rivalry in the pharmaceuticals market in France, 2010
Figure 30: AstraZeneca PLC: revenues & profitability
Figure 31: AstraZeneca PLC: assets & liabilities
Figure 32: GlaxoSmithKline Plc: revenues & profitability
Figure 33: GlaxoSmithKline Plc: assets & liabilities
Figure 34: Pfizer Inc.: revenues & profitability
Figure 35: Pfizer Inc.: assets & liabilities
Figure 36: France pharmaceuticals market value forecast: $ million, 2010–15
Figure 37: Germany pharmaceuticals market value: $ million, 2006–10
Figure 38: Germany pharmaceuticals market segmentation: % share, by value, 2010
Figure 39: Germany pharmaceuticals market share: % share, by value, 2010
Figure 40: Forces driving competition in the pharmaceuticals market in Germany, 2010
Figure 41: Drivers of buyer power in the pharmaceuticals market in Germany, 2010
Figure 42: Drivers of supplier power in the pharmaceuticals market in Germany, 2010
Figure 43: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2010
Figure 44: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2010
Figure 45: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2010
Figure 46: GlaxoSmithKline Plc: revenues & profitability
Figure 47: GlaxoSmithKline Plc: assets & liabilities
Figure 48: Novartis AG: revenues & profitability
Figure 49: Novartis AG: assets & liabilities
Figure 50: Pfizer Inc.: revenues & profitability
Figure 51: Pfizer Inc.: assets & liabilities
Figure 52: Germany pharmaceuticals market value forecast: $ million, 2010–15
Figure 53: Italy pharmaceuticals market value: $ million, 2006–10
Figure 54: Italy pharmaceuticals market segmentation: % share, by value, 2010
Figure 55: Italy pharmaceuticals market share: % share, by value, 2010
Figure 56: Forces driving competition in the pharmaceuticals market in Italy, 2010
Figure 57: Drivers of buyer power in the pharmaceuticals market in Italy, 2010
Figure 58: Drivers of supplier power in the pharmaceuticals market in Italy, 2010
Figure 59: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2010
Figure 60: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2010
Figure 61: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2010
Figure 62: GlaxoSmithKline Plc: revenues & profitability
Figure 63: GlaxoSmithKline Plc: assets & liabilities
Figure 64: Pfizer Inc.: revenues & profitability
Figure 65: Pfizer Inc.: assets & liabilities
Figure 66: Italy pharmaceuticals market value forecast: $ million, 2010–15
Figure 67: Japan pharmaceuticals market value: $ million, 2006–10
Figure 68: Japan pharmaceuticals market segmentation: % share, by value, 2010
Figure 69: Japan pharmaceuticals market share: % share, by value, 2010
Figure 70: Forces driving competition in the pharmaceuticals market in Japan, 2010
Figure 71: Drivers of buyer power in the pharmaceuticals market in Japan, 2010
Figure 72: Drivers of supplier power in the pharmaceuticals market in Japan, 2010
Figure 73: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2010
Figure 74: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2010
Figure 75: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2010
Figure 76: Astellas: revenues & profitability
Figure 77: Astellas: assets & liabilities
Figure 78: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 79: Daiichi Sankyo Co., Ltd.: assets & liabilities
Figure 80: Pfizer Inc.: revenues & profitability
Figure 81: Pfizer Inc.: assets & liabilities
Figure 82: Japan pharmaceuticals market value forecast: $ million, 2010–15
Figure 83: Russia pharmaceuticals market value: $ million, 2006–10
Figure 84: Russia pharmaceuticals market segmentation: % share, by value, 2010
Figure 85: Russia pharmaceuticals market share: % share, by value, 2010
Figure 86: Forces driving competition in the pharmaceuticals market in Russia, 2010
Figure 87: Drivers of buyer power in the pharmaceuticals market in Russia, 2010
Figure 88: Drivers of supplier power in the pharmaceuticals market in Russia, 2010
Figure 89: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2010
Figure 90: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2010
Figure 91: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2010
Figure 92: Novartis AG: revenues & profitability
Figure 93: Novartis AG: assets & liabilities
Figure 94: Pharmstandard OJSC: revenues & profitability
Figure 95: Sanofi-Aventis SA: revenues & profitability
Figure 96: Sanofi-Aventis SA: assets & liabilities
Figure 97: Russia pharmaceuticals market value forecast: $ million, 2010–15
Figure 98: United Kingdom pharmaceuticals market value: $ million, 2006–10
Figure 99: United Kingdom pharmaceuticals market segmentation: % share, by value, 2010
Figure 100: United Kingdom pharmaceuticals market share: % share, by value, 2010
Figure 101: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2010
Figure 102: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2010
Figure 103: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2010
Figure 104: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2010
Figure 105: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2010
Figure 106: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2010
Figure 107: AstraZeneca PLC: revenues & profitability
Figure 108: AstraZeneca PLC: assets & liabilities
Figure 109: GlaxoSmithKline Plc: revenues & profitability
Figure 110: GlaxoSmithKline Plc: assets & liabilities
Figure 111: Pfizer Inc.: revenues & profitability
Figure 112: Pfizer Inc.: assets & liabilities
Figure 113: United Kingdom pharmaceuticals market value forecast: $ million, 2010–15
Figure 114: United States pharmaceuticals market value: $ million, 2006–10
Figure 115: United States pharmaceuticals market segmentation: % share, by value, 2010
Figure 116: United States pharmaceuticals market share: % share, by value, 2010
Figure 117: Forces driving competition in the pharmaceuticals market in the United States, 2010
Figure 118: Drivers of buyer power in the pharmaceuticals market in the United States, 2010
Figure 119: Drivers of supplier power in the pharmaceuticals market in the United States, 2010
Figure 120: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2010
Figure 121: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2010
Figure 122: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2010
Figure 123: GlaxoSmithKline Plc: revenues & profitability
Figure 124: GlaxoSmithKline Plc: assets & liabilities
Figure 125: Johnson & Johnson: revenues & profitability
Figure 126: Johnson & Johnson: assets & liabilities
Figure 127: Merck & Co., Inc.: revenues & profitability
Figure 128: Merck & Co., Inc.: assets & liabilities
Figure 129: Pfizer Inc.: revenues & profitability
Figure 130: Pfizer Inc.: assets & liabilities
Figure 131: United States pharmaceuticals market value forecast: $ million, 2010–15 Skip to top